Table 2. Variables repeatedly measured over the follow-up .

Variables	Phase 1				Phase 2
	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8
Pain intensity score (0–100), median (IQR)
Entire cohort	13.3 (0.0 to 33.3) n = 478	10.0 (0.0 to 30) n = 428	10.0 (10.0 to 26.7) n = 377	6.7 (0.0 to 23.3) n = 349	6.7 (0.0 to 23.3) n = 303	6.7 (0.0 to 23.3) n = 267	6.7 (0.0 to 20.0) n = 245	6.7 (0.0 to 20.0) n = 228
LSRE group	20.0 (6.7 to 36.7) n = 249	13.3 (0.0 to 30) n = 221	10.0 (0.0 to 26.7) n = 201	6.7 (0.0 to 23.3) n = 189	6.7 (0.0 to 30) n = 158	6.7 (0.0 to 23.3) n = 141	6.7 (0.0 to 20) n = 129	8.3 (0.0 to 20) n = 118
NIRE group	10.0 (0.0 to 30.0) n = 229	10.0 (0.0 to 26.7) n = 207	10.0 (0.0 to 26.7) n = 176	6.7 (0.0 to 23.3) n = 160	6.7 (0.0 to 20.0) n = 145	8.3 (0.0 to 22.5) n = 126	6.7 (0.0 to 20.0) n = 116	3.3 (0.0 to 16.7) n = 110
Disability score (0–100), %; n
Entire cohort	n = 478	n = 428	n = 377	n = 349	n = 303	n = 267	n = 245	n = 228
0–5	61.5%; n = 294	70.8%; n = 303	72.9%; n = 275	75.4%; n = 263	75.2%; n = 228	78.7%; n = 210	75.9%; n = 186	78.5%; n = 179
6–10	15.5%; n = 74	10.5%; n = 45	9%; n = 34	9.7%; n = 34	8.9%; n = 27	7.5%; n = 20	8.6%; n = 21	9.2%; n = 21
11–25	11.9%; n = 57	7.9%; n = 34	8%; n = 30	7.7%; n = 27	6.3%; n = 19	5.6%; n = 15	7.3%; n = 18	8.8%; n = 20
26–50	7.7%; n = 37	7.9%; n = 34	8.5%; n = 32	5.2%; n = 18	6.3%; n = 19	6%; n = 16	5.7%; n = 14	2.6%; n = 6
51–75	2.7%; n = 13	2.1%; n = 9	1.1%; n = 4	1.4%; n = 5	2.6%; n = 8	1.5%; n = 4	1.2%; n = 3	0.9%; n = 2
76–100	0.6%; n = 3	0.7%; n = 3	0.5%; n = 2	0.6%; n = 2	0.7%; n = 2	0.7%; n = 2	1.2%; n = 3	0.0%; n = 0
LSRE group	n = 249	n = 221	n = 201	n = 189	n = 158	n = 141	n = 129	n = 118
0–5	60.2%; n = 150	68.3%; n = 151	69.2%; n = 139	74.1%; n = 140	73.4%; n = 116	80.1%; n = 113	75.2%; n = 97	77.1%; n = 91
6–10	15.7%; n = 39	10.4%; n = 23	10.9%; n = 22	12.2%; n = 23	9.5%; n = 15	6.4%; n = 9	9.3%; n = 12	10.2%; n = 12
11–25	12%; n = 30	8.6%; n = 19	7.5%; n = 15	7.9%; n = 15	7%; n = 11	5.7%; n = 8	7%; n = 9	9.3%; n = 11
26–50	9.2%; n = 23	10%; n = 22	10.0%; n = 20	2.6%; n = 5	6.3%; n = 10	5.7%; n = 8	6.2%; n = 8	2.5%; n = 3
51–75	2.4%; n = 6	1.8%; n = 4	1.5%; n = 3	2.1%; n = 4	2.5%; n = 4	0.7%; n = 1	0.0%; n = 0	0.8%; n = 1
76–100	0.4%; n = 1	0.9%; n = 2	1.0%; n = 2	1.1%; n = 2	1.3%; n = 2	1.4%; n = 2	2.3%; n = 3	0.0%; n = 0
NIRE group	n = 229	n = 207	n = 176	n = 160	n = 145	n = 126	n = 116	n = 110
0–5	62.9%; n = 144	73.4%; n = 152	77.3%; n = 136	76.9%; n = 123	77.2%; n = 112	77%; n = 97	76.7%; n = 89	80%; n = 88
6–10	15.3%; n = 35	10.6%; n = 22	6.8%; n = 12	6.9%; n = 11	8.3%; n = 12	8.7%; n = 11	7.8%; n = 9	8.2%; n = 9
11–25	11.8%; n = 27	7.2%; n = 15	8.5%; n = 15	7.5%; n = 12	5.5%; n = 8	5.6%; n = 7	7.8%; n = 9	8.2%; n = 9
26–50	6.1%; n = 14	5.8%; n = 12	6.8%; n = 12	8.1%; n = 13	6.2%; n = 9	6.3%; n = 8	5.2%; n = 6	2.7%; n = 3
51–75	3.1%; n = 7	2.4%; n = 5	0.6%; n = 1	0.6%; n = 1	2.8%; n = 4	2.4%; n = 3	2.6%; n = 3	0.9%; n = 1
76–100	0.9%; n = 2	0.5%; n = 1	0.0%; n = 0	0.0%; n = 0	0.0%; n = 0	0.0%; n = 0	0.0%; n = 0	0.0%; n = 0
Moderate physical activity (min), median (IQR)
Entire cohort	140.0 (25.0 to 360.0) n = 476	50.0 (0.0 to 240.0) n = 425	150.0 (30.0 to 300.0) n = 373	150.0 (37.7 to 300.0) n = 342	150.0 (45.0 to 310.0) n = 303	180.0 (60.0 to 350.0) n = 265	160.0 (50.0 to 350.0) n = 243	180.0 (47.5 to 360.0) n = 227
LSRE group	200.0 (60.0 to 400.0) n = 249	95.0 (0.0 to 300.0) n = 220	180.0 (60.0 to 375.0) n = 197	180.0 (60.0 to 347.5) n = 187	190.0 (60.0 to 395.0) n = 158	200.0 (80.0 to 400.0) n = 140	200.0 (60.0 to 380.0) n = 129	200.0 (60.0 to 390.0) n = 118
NIRE group	75.0 (0.0 to 245.0) n = 227	0.0 (0.0 to 165.0) n = 205	115.0 (0.0 to 240.0) n = 176	120.0 (0.0 to 245.0) n = 155	120.0 (20.0 to 240.0) n = 145	120.0 (30.0 to 270.0) n = 125	125.0 (40.0 to 240.0) n = 114	120.0 (30.0 to 250.0) n = 109
Vigorous physical activity (min), median (IQR)
Entire cohort	30.0 (0.0 to 120.0) n = 476	0.0 (0.0 to 70.0) n = 425	30.0 (0.0 to 120.0) n = 373	30.0 (0.0 to 147.5) n = 342	30.0 (0.0 to 132.5) n = 303	45.0 (0.0 to 130.0) n = 265	40.0 (0.0 to 150.0) n = 243	40.0 (0.0 to 150.0) n = 227
LSRE group	50.0 (0.0 to 165.0) n = 249	(0.0 to 120.0) n = 220	60.0 (0.0 to 160.0) n = 197	60.0 (0.0 to 160.0) n = 187	55.0 (0.0 to 180.0) n = 158	60.0 (7.5 to 200.0) n = 140	50.0 (0.0 to 200.0) n = 129	60.0 (0.0 to 200.0) n = 118
NIRE group	0.0 (0.0 to 60.0) n = 227	0.0 (0.0 to 50.0) n = 205	10.0 (0.0 to 60.0) n = 176	20.0 (0.0 to 110.0) n = 155	20.0 (0.0 to 90.0) n = 145	20.0 (0.0 to 90.0) n = 125	30.0 (0.0 to 120.0) n = 114	20.0 (0.0 to 120.0) n = 109
WHO-5 score (0–25), median (IQR)
Entire cohort	15.0 (10.0 to 19.0) n = 472	15.0 (11.0 to 19.0) n = 424	16.0 (11.0 to 19.0) n = 373	17.0 (12.0 to 20.0) n = 342	13.0 (10.0 to 18.0) n = 300	13.0 (10.0 to 17.0) n = 265	12.0 (10.0 to 17.0) n = 244	12.0 (10.0 to 16.2) n = 228
LSRE group	15.0 (10.0 to 19.0) n = 246	15.0 (11.0 to 20.0) n = 219	16.0 (11.0 to 20.0) n = 198	17.0 (12.0 to 20.0) n = 186	13.0 (10.0 to 17.0) n = 156	13.0 (10.0 to 16.2) n = 140	12.0(10.0 to 16.0) n = 129	11.5 (10.0 to 16.0) n = 120
NIRE group	15.0 (10.0 to 19.0) n = 226	15.0 (11.0 to 19.0) n = 205	15.0 (11.0 to 19.0) n = 175	16.0 (11.0 to 20.0) n = 156	14.0 (10.0 to 19.0) n = 144	13.0 (10.0 to 17.0) n = 125	13.0 (10.0 to 17.0) n = 115	12.5 (10.0 to 17.2) n = 108
SKK- Index (-10–10), mean (SD)
Entire cohort	4.4 (2.6) n = 477	5.7 (5.2) n = 427	4.4 (3.0) n = 376	4.5 (2.8) n = 347	4.4 (2.8) n = 303	4.3 (3.0) n = 267	4.4 (2.8) n = 245	4.4 (3.0) n = 228
LSRE group	4.3 (2.6) n = 249	5.9 (5.5) n = 220	4.4 (3.1) n = 200	4.5 (2.8) n = 188	4.6 (2.8) n = 158	4.4 (3.1) n = 141	4.5 (2.8) n = 129	4.7 (2.7) n = 118
NIRE group	4.5 (2.6) n = 228	5.5 (4.9) n = 207	4.3 (2.8) n = 176	4.4 (2.9) n = 159	4.2 (2.8) n = 145	4.1 (2.9) n = 126	4.3 (3.0) n = 116	4.1 (3.3) n = 110
MOS sleep scale II (0–100), mean (SD)
Entire cohort	67.6 (12.1) n = 477	68.8 (10.7) n = 428	68.1 (11.5) n = 377	68.7 (10.1) n = 349	67.9 (11.3) n = 303	66.6 (12.5) n = 267	69.0 (10.6) n = 245	69.0 (11.2) n = 228
LSRE group	66.8 (12.0) n = 248	69.3 (10.4) n = 221	68.1 (11.1) n = 201	68.7 (10.2) n = 189	67.4 (12.6) n = 158	66.1 (13.1) n = 141	68.9 (11.4) n = 129	70.0 (11.2) n = 118
NIRE group	68.5 (12.2) n = 229	68.3 (11.0) n = 207	68.1 (11.9) n = 176	68.7 (10.2) n = 160	68.4 (9.9) n = 145	67.1 (11.8) n = 126	69.1 (9.7) n = 116	68.0 (11.1) n = 110
GAD 7 questionnaire (0–21), median (IQR)
Entire cohort	6.0 (3.0 to 9.0) n = 478	5.0 (2.0 to 9.0) n = 428	4.0 (2.0 to 8.0) n = 377	4.0 (1.0 to 8.0) n = 349	4.0 (2.0 to 7.0) n = 303	4.0 (1.0 to 7.0) n = 267	3.0 (1.0 to 7.0) n = 245	4.0 (1.0 to 7.0) n = 228
LSRE group	5.0 (2.0 to 9.0) n = 249	4.0 (2.0 to 8.0) n = 221	4.0 (2.0 to 8.0) n = 201	4.0 (1.0 to 8.0) n = 189	4.0 (1.0 to 7.0) n = 158	3.0 (1.0 to 7.0) n = 141	3.0 (1.0 to 7.0) n = 129	3.0 (0.0 to 7.0) n = 118
NIRE group	6.0 (3.0 to 9.0) n = 229	6.0 (3.0 to 9.0) n = 207	5.0 (2.0 to 7.2) n = 176	4.0 (2.0 to 7.0) n = 160	4.0 (2.0 to 6.0) n = 145	4.0 (1.0 to 7.0) n = 126	3.0 (1.0 to 6.0) n = 116	4.0 (2.0 to 7.0) n = 110

GAD 7, Generalized Anxiety Disorder scale-7; MOS, Medical Outcomes Study 12-item Sleep Scale; SKK, Self-concordance Scale for Exercise Motivation; WHO, World Health Organization – Five Well-Being Index (WHO-5); LSRE, Live-Streamed – > Recorded Exercise; NIRE, No Intervention – > Recorded Exercise; IQR, 25% to 75% interquartile range.